Showing results (91-100 of 120) with videos related to
Sort By:
Pageof 12
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2009
EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell linesDorine A Bax, Nathalie Gaspar, Suzanne E Little, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 21, 2021
Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group StudyAlberto Garaventa, Ulrike Poetschger, Dominique Valteau-Couanet, et al.JCO Clinical Cancer Informatics|October 18, 2021
Pediatric Cancer Data Commons: Federating and Democratizing Data for Childhood Cancer ResearchAlejandro Plana, Brian Furner, Monica Palese, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2003
Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumorsSean Carlin, Rob J Mairs, Anthony G McCluskey, et al.Cancer Research|March 17, 2019
MRI Imaging of the Hemodynamic Vasculature of Neuroblastoma Predicts Response to Antiangiogenic TreatmentKonstantinos Zormpas-Petridis, Neil P Jerome, Matthew D Blackledge, et al.Journal of Neuro-Oncology|May 16, 2016
Pseudoprogression in children, adolescents and young adults with non-brainstem high grade glioma and diffuse intrinsic pontine gliomaFernando Carceller, Lucy A Fowkes, Komel Khabra, et al.European Journal of Cancer (Oxford, England : 1990)|June 4, 2016
Implementation of mechanism of action biology-driven early drug development for children with cancerAndrew D J Pearson, Ralf Herold, Raphaël Rousseau, et al.Cancers|February 5, 2020
Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau-Couanet, et al.The Lancet. Oncology|November 17, 2018
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trialRuth Ladenstein, Ulrike Pötschger, Dominique Valteau-Couanet, et al.European Journal of Cancer (Oxford, England : 1990)|March 15, 2022
ACCELERATE - Five years accelerating cancer drug development for children and adolescentsAndrew D J Pearson, Susan L Weiner, Peter C Adamson, et al.Pageof 12